The Rogosin Institute is an independent, not-for-profit treatment and research center with facilities throughout New York City that treat patients with kidney disease, including dialysis and kidney transplantation; lipid disorders; and hypertension.

During the past decade, The Rogosin Institute conducted 13 clinical trials. In the 10-year time frame, 13 clinical trials started and 7 clinical trials were completed, i.e. on average, 53.8% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "The Rogosin Institute" #1 sponsor was "The Rogosin Institute" with 18 trials, followed by "Deka Research and Development" with 2 trials sponsored, "Otsuka Pharmaceutical Development & Commercialization, Inc." with 2 trials sponsored, "Abbott" with 1 trials sponsored and "Concert Pharmaceuticals" with 1 trials sponsored. Other sponsors include 0 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "The Rogosin Institute" #1 collaborator was "Weill Medical College of Cornell University" with 13 trials as a collaborator, "New York Presbyterian Hospital" with 3 trials as a collaborator, "CVS Kidney Care LLC." with 2 trials as a collaborator, "Otsuka Pharmaceutical Co., Ltd." with 2 trials as a collaborator and "Rogosin Institute" with 2 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "The Rogosin Institute" are "End Stage Renal Disease" (6 trials), "Chronic Kidney Disease" (4 trials), "ADPKD" (2 trials), "Autosomal Dominant Polycystic Kidney" (2 trials) and "Chronic Pain" (2 trials). Many other conditions were trialed in "The Rogosin Institute" in a lesser frequency.

Most popular intervention types in "The Rogosin Institute" are "Drug" (10 trials), "Device" (6 trials), "Other" (4 trials), "Behavioral" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "HemoCare™ Hemodialysis System" (2 trials), "Tolvaptan" (2 trials), "Active tDCS" (1 trials) and "Aliskiren" (1 trials). Other intervention names were less common.

The vast majority of trials in "The Rogosin Institute" are 28 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "The Rogosin Institute". undefined are not yet recruiting, 6 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 17 completed trials in The Rogosin Institute, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in The Rogosin Institute, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 10 trials that are defined as “Not Applicable".